Review ArticleReview

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

Long Jia, Qi Zhang and Rongxin Zhang
Cancer Biology & Medicine May 2018, 15 (2) 116-123; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0086

References

  1. 1.↵
    2. Ishida Y,
    3. Agata Y,
    4. Shibahara K,
    5. Honjo T.
    Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11: 3887–95.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Chen LP,
    3. Ashe S,
    4. Brady WA,
    5. Hellström I,
    6. Hellström KE,
    7. Ledbetter JA, et al.
    Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71: 1093–102.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Agata Y,
    3. Kawasaki A,
    4. Nishimura H,
    5. Ishida Y,
    6. Tsubat T,
    7. Yagita H, et al.
    Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8: 765–72.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    2. Iwai Y,
    3. Okazaki T,
    4. Nishimura H,
    5. Kawasaki A,
    6. Yagita H,
    7. Honjo T.
    Microanatomical localization of PD-1 in human tonsils. Immunol Lett. 2002; 83: 215–20.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Freeman GJ,
    3. Long AJ,
    4. Iwai Y,
    5. Bourque K,
    6. Chernova T,
    7. Nishimura H, et al.
    Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192: 1027–34.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Ishida M,
    3. Iwai Y,
    4. Tanaka Y,
    5. Okazaki T,
    6. Freeman GJ,
    7. Minato N, et al.
    Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84: 57–62.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.
    2. Iwai Y,
    3. Terawaki S,
    4. Ikegawa M,
    5. Okazaki T,
    6. Honjo T.
    PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003; 198: 39–50.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    2. Takada K,
    3. Toyokawa G,
    4. Shoji F,
    5. Okamoto T,
    6. Maehara Y.
    The significance of the PD-L1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers. Clin Lung Cancer. 2017; 19: 120–9.
    OpenUrl
  9. 9.↵
    2. Butte MJ,
    3. Keir ME,
    4. Phamduy TB,
    5. Sharpe AH,
    6. Freeman GJ.
    Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27: 111–22.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Mishra AK,
    3. Kadoishi T,
    4. Wang XG,
    5. Driver E,
    6. Chen ZG,
    7. Wang XJ, et al.
    Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T cells co-expressing PD-1 and LAG-3 inhibitory receptors. Oncotarget. 2016; 7: 81341–56.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Keir ME,
    3. Liang SC,
    4. Guleria I,
    5. Latchman YE,
    6. Qipo A,
    7. Albacker LA, et al.
    Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203: 883–95.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Iwai Y,
    3. Ishida M,
    4. Tanaka Y,
    5. Okazaki T,
    6. Honjo T,
    7. Minato N.
    Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002; 99: 12293–7.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Taube JM,
    3. Anders RA,
    4. Young GD,
    5. Xu HY,
    6. Sharma R,
    7. McMiller TL, et al.
    Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra37.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Thompson RH,
    3. Gillett MD,
    4. Cheville JC,
    5. Lohse CM,
    6. Dong HD,
    7. Webster WS, et al.
    Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004; 101: 17174–9.
    OpenUrlAbstract/FREE Full Text
  15. 15.
    2. Nakanishi J,
    3. Wada Y,
    4. Matsumoto K,
    5. Azuma M,
    6. Kikuchi K,
    7. Ueda S.
    Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007; 56: 1173–82.
    OpenUrlCrossRefPubMed
  16. 16.
    2. Ohigashi Y,
    3. Sho M,
    4. Yamada Y,
    5. Tsurui Y,
    6. Hamada K,
    7. Ikeda N, et al.
    Clinical significance of programmed Death-1 Ligand-1 and programmed Death-1 Ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005; 11: 2947–53.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    2. Nomi T,
    3. Sho M,
    4. Akahori T,
    5. Hamada K,
    6. Kubo A,
    7. Kanehiro H, et al.
    Clinical significance and therapeutic potential of the programmed Death-1 Ligand/programmed Death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13: 2151–7.
    OpenUrlAbstract/FREE Full Text
  18. 18.
    2. Hamanishi J,
    3. Mandai M,
    4. Iwasaki M,
    5. Okazaki T,
    6. Tanaka Y,
    7. Yamaguchi K, et al.
    Programmed cell Death 1 Ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007; 104: 3360–5.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    2. Ghebeh H,
    3. Mohammed S,
    4. Al-Omair A,
    5. Qattan A,
    6. Lehe C,
    7. Al-Qudaihi G, et al.
    The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8: 190–8.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Duraiswamy J,
    3. Freeman GJ,
    4. Coukos G.
    Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013; 73: 6900–12.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Somasundaram A,
    3. Socinski MA,
    4. Villaruz LC.
    Immune checkpoint blockade in lung cancer. Discov Med. 2016; 22: 55–65.
    OpenUrl
  22. 22.↵
    2. Jiricny J.
    The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006; 7: 335–46.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    2. Richman S.
    Deficient mismatch repair: read all about it (review). Int J Oncol. 2015; 47: 1189–202.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Gubin MM,
    3. Zhang XL,
    4. Schuster H,
    5. Caron E,
    6. Ward JP,
    7. Noguchi T, et al.
    Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515: 577–81.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.
    2. Schumacher TN,
    3. Schreiber RD.
    Neoantigens in cancer immunotherapy. Science. 2015; 348: 69–74.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    2. Ward JP,
    3. Gubin MM,
    4. Schreiber RD.
    The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol. 2016; 130: 25–74.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Giannakis M,
    3. Mu XJ,
    4. Shukla SA,
    5. Qian ZR,
    6. Cohen O,
    7. Nishihara R, et al.
    Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016; 15: 857–65.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Le DT,
    3. Durham JN,
    4. Smith KN,
    5. Wang H,
    6. Bartlett BR,
    7. Aulakh LK, et al.
    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–13.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Diaz L,
    3. Marabelle A,
    4. Kim TW,
    5. Geva R,
    6. Van Cutsem E,
    7. André T, et al.
    386p Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann Oncol. 2017; 28: mdx367.020.
    OpenUrl
  30. 30.↵
    2. Seiwert TY,
    3. Burtness B,
    4. Mehra R,
    5. Weiss J,
    6. Berger R,
    7. Eder JP, et al.
    Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17: 956–65.
    OpenUrlCrossRefPubMed
  31. 31.↵
    U.S. FOOD & DRUG. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. 2017.
  32. 32.↵
    2. Escudier B,
    3. Motzer RJ,
    4. Sharma P,
    5. Wagstaff J,
    6. Plimack ER,
    7. Hammers HJ, et al.
    Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025. Eur Urol. 2017; 72: 368–76.
    OpenUrlPubMed
  33. 33.↵
    2. George S,
    3. Motzer RJ,
    4. Hammers HJ,
    5. Redman BG,
    6. Kuzel TM,
    7. Tykodi SS, et al.
    Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016; 2: 1179–86.
    OpenUrl
  34. 34.↵
    2. Brahmer J,
    3. Reckamp KL,
    4. Baas P,
    5. Crinò L,
    6. Eberhardt WEE,
    7. Poddubskaya E, et al.
    nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373: 1627–39.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Hamanishi J,
    3. Mandai M,
    4. Ikeda T,
    5. Minami M,
    6. Kawaguchi A,
    7. Murayama T, et al.
    Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015; 33: 4015–22.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Rittmeyer A,
    3. Barlesi F,
    4. Waterkamp D,
    5. Park K,
    6. Ciardiello F,
    7. Von Pawel J, et al.
    atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389: 255–65.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Powles T,
    3. O'Donnell PH,
    4. Massard C,
    5. Arkenau HT,
    6. Friedlander TW,
    7. Hoimes CJ, et al.
    Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017; 3: e172411.
  38. 38.↵
    2. Iwai Y,
    3. Hamanishi J,
    4. Chamoto K,
    5. Honjo T.
    Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017; 24: 26.
    OpenUrlPubMed
  39. 39.↵
    2. Boutros C,
    3. Tarhini A,
    4. Routier E,
    5. Lambotte O,
    6. Ladurie FL,
    7. Carbonnel F, et al.
    Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13: 473–86.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Pardoll DM.
    The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252–64.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    2. Langer CJ,
    3. Gadgeel SM,
    4. Borghaei H,
    5. Papadimitrakopoulou VA,
    6. Patnaik A,
    7. Powell SF, et al.
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016; 17: 1497–508.
    OpenUrlCrossRefPubMed
  42. 42.↵
    2. Wolchok JD,
    3. Kluger H,
    4. Callahan MK,
    5. Postow MA,
    6. Rizvi NA,
    7. Lesokhin AM, et al.
    nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122–33.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    2. Postow MA,
    3. Chesney J,
    4. Pavlick AC,
    5. Robert C,
    6. Grossmann K,
    7. McDermott D, et al.
    nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015; 372: 2006–17.
    OpenUrlCrossRefPubMed
  44. 44.
    2. Schachter J,
    3. Ribas A,
    4. Long GV,
    5. Arance A,
    6. Grob JJ,
    7. Mortier L, et al.
    pembrolizumab versus Ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390: 1853–62.
    OpenUrlCrossRefPubMed
  45. 45.
    2. Reck M,
    3. Rodríguez-Abreu D,
    4. Robinson AG,
    5. Hui RN,
    6. Csőszi T,
    7. Fülöp A, et al.
    pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375: 1823–33.
    OpenUrlCrossRefPubMed
  46. 46.
    2. Mehra R,
    3. Seiwert TY,
    4. Mahipal A,
    5. Weiss J,
    6. Berger R,
    7. Eder JP, et al.
    Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. J Clin Oncol. 2016; 34: 6012.
    OpenUrl
  47. 47.
    2. Chen R,
    3. Zinzani PL,
    4. Fanale MA,
    5. Armand P,
    6. Johnson NA,
    7. Brice P, et al.
    Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35: 2125–32.
    OpenUrlCrossRefPubMed
  48. 48.
    2. Balar AV,
    3. Castellano D,
    4. O'Donnell PH,
    5. Grivas P,
    6. Vuky J,
    7. Powles T, et al.
    First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18: 1483–92.
    OpenUrlCrossRefPubMed
  49. 49.
    2. Fuchs CS,
    3. DoiT ,
    4. Jang RWJ,
    5. Muro K,
    6. Satoh T,
    7. Machado M, et al.
    KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017; 35: 4003.
    OpenUrl
  50. 50.
    2. Weber JS,
    3. D’Angelo SP,
    4. Minor D,
    5. Hodi FS,
    6. Gutzmer R,
    7. Neyns B, et al.
    nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16: 375–84.
    OpenUrlCrossRefPubMed
  51. 51.
    2. Weber J,
    3. Mandala M,
    4. Del Vecchio M,
    5. Gogas HJ,
    6. Arance AM,
    7. Cowey CL, et al.
    Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377: 1824–35.
    OpenUrlCrossRefPubMed
  52. 52.
    2. Motzer RJ,
    3. Escudier B,
    4. McDermott DF,
    5. George S,
    6. Hammers HJ,
    7. Srinivas S, et al.
    nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373: 1803–13.
    OpenUrlCrossRefPubMed
  53. 53.
    2. Younes A,
    3. Santoro A,
    4. Shipp M,
    5. Zinzani PL,
    6. Timmerman JM,
    7. Ansell S, et al.
    nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17: 1283–94.
    OpenUrlCrossRefPubMed
  54. 54.
    2. Ferris RL,
    3. Blumenschein G Jr.,
    4. Fayette J,
    5. Guigay J,
    6. Colevas AD,
    7. Licitra L, et al.
    nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856–67.
    OpenUrlCrossRefPubMed
  55. 55.
    2. Sharma P,
    3. Retz M,
    4. Siefker-Radtke A,
    5. Baron A,
    6. Necchi A,
    7. Bedke J, et al.
    nivolumab in metastatic urothelial carcinoma after platinum therapy (Checkmate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18: 312–22.
    OpenUrlCrossRefPubMed
  56. 56.
    2. El-Khoueiry AB,
    3. Sangro B,
    4. Yau T,
    5. Crocenzi TS,
    6. Kudo M,
    7. Hsu C, et al.
    nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389: 2492–502.
    OpenUrlCrossRefPubMed
  57. 57.
    2. Overman MJ,
    3. McDermott R,
    4. Leach JL,
    5. Lonardi S,
    6. Lenz HJ,
    7. Morse MA, et al.
    nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (Checkmate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18: 1182–91.
    OpenUrlCrossRefPubMed
  58. 58.
    2. Kaufman HL,
    3. Russell J,
    4. Hamid O,
    5. Bhatia S,
    6. Terheyden P,
    7. D’Angelo SP, et al.
    avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17: 1374–85.
    OpenUrlCrossRefPubMed
  59. 59.
    2. Patel MR,
    3. Ellerton J,
    4. Infante JR,
    5. Agrawal M,
    6. Gordon M,
    7. Aljumaily R, et al.
    avelumab in metastatic urothelial carcinoma after platinum failure (javelin solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2017; 19: 51–64.
    OpenUrl
  60. 60.
    2. Rosenberg JE,
    3. Hoffman-Censits J,
    4. Powles T,
    5. Van Der Heijden MS,
    6. Balar AV,
    7. Necchi A, et al.
    atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387: 1909–20.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords